Skip to main content
    S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.15
    -0.03 (-2.54%)

    Market Cap: $66.97M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(24/34)
    Avg Surprise
    +89.00%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.14 - $-0.14
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$-0.14
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.44
    Range$-0.44 - $-0.44
    1 analysts
    Revenue Consensus
    $258000
    Range$258000 - $258000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 12
    		$-0.16$-0.19+15.79%Beat-433.3%
    Mar 26
    Reported May 13
    		$-0.13N/AN/ABeat+49.7%
    Dec 25
    Reported Mar 26
    		$0.53$-0.20+365.45%Beat+244.7%
    Sep 25
    Reported Nov 13
    		$-0.13$-0.25+48.00%Beat+59.4%
    Jun 25
    Reported Aug 12
    		$-0.03N/A+92.11%Beat+90.9%
    Mar 25
    Reported May 13
    		$-0.25$-0.44+43.18%Beat-4.2%
    Dec 24
    Reported Mar 27
    		$-0.37$-0.31-18.35%Miss-138.2%
    Sep 24
    Reported Nov 14
    		$-0.32$-0.36+11.11%Beat-900.0%
    Jun 24
    Reported Aug 5
    		$-0.33$-0.38+13.16%Beat-43.5%
    Mar 24
    Reported May 15
    		$-0.24$-0.06-300.00%Miss+4.0%
    Dec 23
    Reported Mar 13
    		$0.96$-0.10+1060.00%Beat+74.5%
    Sep 23
    Reported Nov 13
    		$0.04$-0.03+233.33%Beat+112.1%
    Jun 23
    Reported Aug 10
    		$-0.23$-0.37+37.84%Beat+46.5%
    Mar 23
    Reported May 11
    		$-0.25$-0.26+3.85%Beat+75.2%
    Dec 22
    Reported Mar 30
    		$0.55$0.04+1275.00%Beat+161.1%
    Sep 22
    Reported Nov 14
    		$-0.33$-0.24-37.50%Miss+52.9%
    Jun 22
    Reported Aug 10
    		$-0.43N/A+53.76%Beat+31.7%
    Mar 22
    Reported May 16
    		$-1.01$-0.95-6.32%Miss-53.0%
    Dec 21
    Reported Mar 31
    		$-0.90$-0.75-20.00%Miss-32.4%
    Sep 21
    Reported Nov 10
    		$-0.70$-0.66-6.06%Miss+18.6%
    Jun 21
    Reported Aug 5
    		$-0.63$-0.75+16.00%Beat+25.9%
    Mar 21
    Reported May 6
    		$-0.66$-0.63-4.76%Miss+44.5%
    Dec 20
    Reported Mar 11
    		$-0.68$-0.74+8.11%Beat+50.0%
    Sep 20
    Reported Nov 5
    		$-0.86$-0.89+3.37%Beat+9.5%
    Jun 20
    Reported Aug 6
    		$-0.85$-1.13+24.78%Beat-14.9%
    Mar 20
    Reported May 8
    		$-1.19$-1.25+4.80%Beat-310.3%
    Dec 19
    Reported Mar 16
    		$-1.36$-1.08-25.93%Miss-126.7%
    Sep 19
    Reported Nov 4
    		$-0.95$-0.85-11.76%Miss-58.3%
    Jun 19
    Reported Aug 8
    		$-0.74$-0.86+13.95%Beat-7.2%
    Mar 19
    Reported May 9
    		$-0.29N/A+62.34%Beat+60.8%
    Dec 18
    Reported Mar 14
    		$-0.60$-0.75+20.00%Beat+98.3%
    Sep 18
    Reported Nov 8
    		$-0.60$-0.63+4.76%Beat+79.7%
    Jun 18
    Reported Aug 9
    		$-0.69$-0.77+10.39%Beat-35.3%
    Mar 18
    Reported Apr 2
    		$-0.74$-1.20+38.33%Beat-
    Sep 17
    Reported Dec 14
    		$-36.02$-35.07-2.71%Miss-
    Jun 17
    Reported Aug 30
    		$-2.96$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.51$0.00N/AMiss-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio9.98EV/EBITDA2.65x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin15.70%Operating Margin14.10%
    ROE19.20%ROIC10.74%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.12xQuick Ratio6.12x
    Trading Statistics
    Beta1.50Avg Volume851.22K
    52-Week High$3.0852-Week Low$1.08

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.19
    SMA 20$1.19
    SMA 50$1.20
    SMA 200$2.07
    EMA 10$1.18
    EMA 20$1.19
    EMA 50$1.29
    EMA 200$1.80

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 27.0+DI: 21.8-DI: 15.1

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down24.0
    PSAR$1.36

    Bollinger Bands

    Upper Band$1.31
    Lower Band$1.07
    %B Position1997%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    44.5

    Momentum Oscillators

    Stoch %K17.5
    Stoch %D16.2
    Williams %R-88.9
    ROC (10d)-4.2%
    Momentum-0.05
    CCI (20d)-49.8
    MFI (14d)41.5

    Volatility Measures

    ATR (14d)$0.07(6.2%)
    StdDev (20d)0.06
    Hist Vol85.7%(High)

    Volume Flow

    VWAP$1.17
    OBV202.8M
    AD Line41.9M
    CMF (20d)-0.253

    Volume Metrics

    Avg Vol (20d)911.7K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.27

    Pivot Points

    R3$1.27
    R2$1.24
    R1$1.21
    Pivot Point$1.19
    S1$1.16
    S2$1.13
    S3$1.10

    Advanced Oscillators

    TSI-6.35
    Ultimate Osc33.5
    KST2.92

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$258,000$41.30M$5.44M$14.19M$5.87M$15.04M$13.47M$10.20M$9.27M$73.52M$25.47M
    Cost of Revenue$0$0N/A$0$0$0$94.63M$0$0$0$49.43M$0
    Gross Profit$0$258,000$41.30M$5.44M$14.19M$5.87M$15.04M$13.47M$10.20M$9.27M$73.52M$25.47M
    Operating Expenses$9.93M$7.80M$9.89M$13.36M$16.63M$20.61M$36.77M$32.06M$29.26M$23.25M$22.99M$27.41M
    R&D$3.43M$2.91M$5.59M$8.60M$10.67M$13.61M$28.84M$26.86M$23.73M$17.33M$16.56M$16.39M
    SG&A$6.49M$4.89M$4.30M$4.17M$5.88M$6.82M$7.06M$5.20M$5.53M$5.92M$6.43M$5.71M
    Operating Income$-9,926,000$-7,538,000$31.41M$-7,916,000$-2,444,000$-14,731,000$-21,725,000$-18,593,000$-19,061,000$-13,982,000$50.53M$-1,934,000
    Interest Income$377,000$336,000$376,000$532,000$740,000$864,000$1.03M$1.18M$1.20M$1.33M$1.04M$950,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-9,552,000$-7,203,000$31.78M$-7,382,000$-1,700,000$-13,866,000$-20,598,000$-17,437,000$-17,862,000$-12,669,000$51.58M$-994,000
    Income Tax Expense$0$0$0$0$0$0$0$290,000$0$0$387,000$2.21M
    Net Income$-9,552,000$-7,203,000$31.52M$-7,382,000$-1,700,000$-13,866,000$-20,888,000$-17,147,000$-17,862,000$-12,669,000$51.19M$-3,205,000
    EBITDA$-9,929,000$-7,539,000$31.41M$-7,914,000$-2,440,000$-14,730,000$-21,626,000$-18,619,000$-19,058,000$-13,996,000$50.57M$-1,836,000
    EBIT$-9,929,000$-7,539,000$31.41M$-7,914,000$-2,440,000$-14,730,000$-21,626,000$-18,619,000$-19,060,000$-13,996,000$50.54M$-1,944,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SPRO

    Government Contracts

    Gov Obligations (TTM)
    -$599066
    Gov Obligations / Revenue
    -1.0%
    Obligations YoY
    -106.1%
    Active Awards
    2
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

    Spero Therapeutics announced that its President and CEO, Esther Rajavelu, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026...

    The Manila Times•10/15/26•Neutral

    Spero's CEO will join a New York fireside chat; a replay will be available for about 90 days.

    Spero Therapeutics (SPRO) announced that its President and CEO, Esther Rajavelu, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026...

    Stock Titan•10/15/26•Neutral

    Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock

    Spero Therapeutics approved 556,000 equity awards for new employees on October 1, 2026, comprising restricted stock units and stock options. These grants aim to incentivize employees and are tied to continued employment...

    ad-hoc-news.de•10/15/26•Neutral

    Spero Therapeutics, Inc. (SPRO) Options Chain - Yahoo Finance

    This page provides the options chain data for Spero Therapeutics, Inc. (SPRO), including details for both call and put options. It lists various strike prices, last trade dates, last prices, bid/ask prices, volume...

    Yahoo! Finance Canada•10/15/26•Neutral

    Spero Therapeutics targets SP001 trial for 2027: Spero Therapeutics stock gains 3.85 percent

    Spero Therapeutics (SPRO) aims to start a Phase II trial for its SP001 drug in the second quarter of 2027, marking a strategic shift towards immunology. The company's stock rose 3.85 percent on October 8, 2026...

    AD HOC NEWS•10/8/26•Somewhat-Bullish

    SPRO Valuation and Fair Value

    P/E
    10.0x
    EV/EBITDA
    2.7x
    PEG
    0.0x
    P/B
    1.5x
    See GNG's fair value

    SPRO Profitability: Margins, ROIC and FCF

    Operating margin
    14.1%
    Net margin
    15.7%
    ROIC
    10.7%
    ROE
    19.2%
    FCF margin
    41.7%

    SPRO Competitors

    CompanyTicker
    Microbot Medical IncMBOT
    Champions Oncology IncCSBR
    Cingulate IncCING
    Neumora Therapeutics, Inc.NMRA
    Heron TherapeutiHRTX
    XBiotech IncXBIT
    Fortress Biotech IncFBIO
    Verrica Pharmaceuticals IncVRCA

    Sector: Healthcare

    SPRO Bull Case vs Bear Case

    Bull case

    • SPRO converts 41.7% of revenue into free cash flow.
    • SPRO beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • SPRO's quarterly revenue changed -95.6% year over year.

    SPRO Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    29.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    SPRO Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About SPRO

    Does SPRO pay dividends?

    Spero Therapeutics Inc (SPRO) has a dividend payment track record. See the SPRO dividend history page for its current payment status, TTM yield, and recorded payments.

    What is SPRO's P/E ratio?

    Spero Therapeutics Inc has a price-to-earnings (P/E) ratio of 9.98.

    What is SPRO's market cap?

    Spero Therapeutics Inc (SPRO) has a market capitalization of $66.97M with a current stock price of $1.15.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In